ArticleVirchows Archiv : an international journal of pathology2026
Immunohistochemical expression of Ki-67, INSM1, and SSTR2A in medullary thyroid carcinoma: correlation with tumour size, vascular invasion, and biochemical outcome.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the management of medullary thyroid carcinoma (MTC), current prognostic tools have limited discriminatory power, and no widely accepted tissue markers are available aside from proliferative activity and tumour necrosis, recently validated in a grading system. Herein, we assess the prognostic value of selected immunohistochemical biomarkers in MTC: proliferation index Ki-67, insulinoma-associated protein 1 (INSM1), and somatostatin receptor subtype 2A (SSTR2A). We retrospectively analysed 43 patients diagnosed at our centre between October 2003 and July 2024 with histologically confirmed MTC (mean follow-up, 52.5 months). Expression of Ki-67 (> 3%), INSM1, and SSTR2A was evaluated on formalin-fixed, paraffin-embedded tissue sections. Associations between these biomarkers and clinicopathological variables, as well as biochemical cure, were analyzed. Additionally, we compared 13 patients with double tumours (DT)-with medullary and papillary/follicular components-to the remaining 30 patients to identify significant differences. A Ki-67 index > 3% significantly correlated with larger tumour size (26.0 mm vs 9.6 mm; p < 0.001) and vascular invasion (80% vs 31.6%; p = 0.035). INSM1 expression was associated with larger tumour size (12.9 mm vs 3.2 mm; p = 0.021), vascular invasion (43.2% vs 0%; p = 0.042), and lower biochemical cure rate (54.1% vs 100%; p = 0.033). SSTR2A expression correlated with biochemical cure (100% vs 54.1%; p = 0.033) and was more frequent in DT patients (66.7% vs 24.3%; p = 0.036). Among all comparisons, only SSTR2A expression significantly differed between DTs and other tumours. In conclusion, Ki-67 and INSM1 identify patients with more aggressive MTC, while SSTR2A defines a favourable subgroup with complete remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.